| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 2115029 | Cancer Letters | 2008 | 11 Pages | 
Abstract
												We report here the generation and characterization of EGF-IL-18 fusion protein as an anti-tumor reagent. The epidermal growth factor (EGF) and interleukin-18 (IL-18) fusion protein was shown to induce interferon-γ (IFNγ) expression and secretion in KG-1 cells, and to promote PBMNC proliferation. It also stimulated activation of CD4+ T cells, and increased other immune responses. Moreover, EGF-IL-18 could induce significant tumor regression in SMMC-7721-xenografted Balb/c nude mice when administered together with peritumoral injection of X-ray-irradiated NK-92 cells, and this regression is associated with arresting of the tumor cells in G1 phase and induction of apoptosis.
Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Cancer Research
												
											Authors
												Jianxin Lu, Y. Peng, Z.J. Zheng, J.H. Pan, Yangde Zhang, Yidong Bai, 
											